Heart Failure After Heart Transplantation Due to Chronic Rejection

NCT ID: NCT03808324

Last Updated: 2019-01-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-31

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the prevalence of allograft vasculopathy and unexplained graft dysfunction during long-term follow-up after heart transplantation. Risk factors as well diagnostic approaches will be investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During long-term follow-up heart transplant recipients are at risk of developing different complications that are likely to affect quality of life and survival. The most common cause of death during the later stages after heart transplantation is cardiac allograft vasculopathy, followed by unexplained graft dysfunction. In this study, advanced imaging techniques will be used to describe the frequency of these two complications, examine possible risk factors and study consequences on functional capacity and quality of life. Further, the investigators will investigate whether it is feasible to screen for these conditions with non-invasive imaging methods. By studying patients that have performed cardiac transplantation between 10 and 20 years ago, the investigators expect to have a significant proportion of patients with these pathological conditions. Methods that will be used include cardiac magnetic resonance imaging, coronary flow velocity reserve assessment, right heart catheterization and coronary imaging with angiography and optical coherence tomography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Allograft Vasculopathy Chronic Rejection of Cardiac Transplant Graft Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heart transplant recipients

Group Type EXPERIMENTAL

Diagnostic investigations

Intervention Type DIAGNOSTIC_TEST

Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic investigations

Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heart transplant performed more than 10 years and less than 21 years ago
* Scheduled yearly post-transplant control
* Signed informed consent

Exclusion Criteria

* Estimated GFR \< 30 mL/min/1,73m2
* Radiographic contrast allergy
* Severe asthma or COLD with FEV1 \< 50%
* Second or third degree AV block
* Pregnancy
* In the Investigator's opinion, the patient has a clinically significant disease that could be adversely affected by study participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sahlgrenska University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sorosh Esmaily

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sahlgrenska University Hospital

Gothenburg, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sorosh Esmaily, MD

Role: primary

+46707488821

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AVALON

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Allograft Dysfunction in Heart Transplant
NCT03102125 RECRUITING PHASE4
Antibodies and Liver Retransplantation
NCT03815864 ACTIVE_NOT_RECRUITING